PT - JOURNAL ARTICLE AU - Musinguzi, Allan AU - Kasidi, Joan R. AU - Kadota, Jillian L. AU - Welishe, Fred AU - Nakitende, Anne AU - Akello, Lydia AU - Nakimuli, Jane AU - Kunihira, Lynn T. AU - Opira, Bishop AU - Baik, Yeonsoo AU - Patel, Devika AU - Sammann, Amanda AU - Berger, Christopher A. AU - Aschmann, Hélène E. AU - Nahid, Payam AU - Belknap, Robert AU - Kamya, Moses R. AU - Handley, Margaret A. AU - Phillips, Patrick PJ AU - Kiwanuka, Noah AU - Katamba, Achilles AU - Dowdy, David W. AU - Cattamanchi, Adithya AU - Semitala, Fred C. AU - Katahoire, Anne R. TI - Evaluating the implementation of weekly rifapentine-isoniazid (3HP) for tuberculosis prevention among people living with HIV in Uganda: A qualitative evaluation of the 3HP Options Trial AID - 10.1101/2024.08.19.24308041 DP - 2024 Jan 01 TA - medRxiv PG - 2024.08.19.24308041 4099 - http://medrxiv.org/content/early/2024/08/22/2024.08.19.24308041.short 4100 - http://medrxiv.org/content/early/2024/08/22/2024.08.19.24308041.full AB - Three months of isoniazid-rifapentine (3HP) is being scaled up for tuberculosis (TB) preventive treatment (TPT) among people living with HIV (PLHIV) in high-burden settings. More evidence is needed to identify factors influencing successful 3HP delivery. We conducted a qualitative assessment of 3HP delivery nested within the 3HP Options Trial, which compared three optimized strategies for delivering 3HP: facilitated directly observed therapy (DOT), facilitated self-administered therapy (SAT), and patient choice between facilitated DOT and facilitated SAT at the Mulago HIV/AIDS clinic in Kampala, Uganda. We conducted 72 in-depth interviews among PLHIV purposively selected to investigate factors influencing 3HP acceptance and completion. We conducted ten key informant interviews with healthcare providers (HCPs) involved in 3HP delivery to identify facilitators and barriers at the clinic level. We used post-trial 3HP delivery data to assess sustainability. We conducted an inductive thematic analysis and aligned the emergent themes with the RE-AIM framework dimensions to report implementation outcomes. Understanding the need for TPT, once-weekly dosing, shorter duration, and perceived 3HP safety enhanced acceptance overall. Treatment monitoring by HCPs and reduced risk of HIV status disclosure enabled DOT acceptance. Dosing autonomy enabled SAT acceptance. Switching between DOT and SAT as required enabled acceptance for patient choice. Dosing reminders, reimbursement for clinical visits, and social support enabled 3HP completion; pill burden, side effects, and COVID-19-related treatment restrictions hindered completion. All HCPs were trained and participated in 3HP delivery with high fidelity. Training, care integration, and collaboration among HCPs enabled, whereas initial concerns about 3HP safety among HCPs delayed 3HP adoption and implementation. SAT was maintained post-trial; DOT was discontinued due to inadequate ongoing financial support beyond the study period. Facilitated delivery strategies made 3HP treatment convenient for PLHIV and were feasible and implemented with high fidelity by HCPs. However, the costs of 3HP facilitation may limit wider scale-up.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov (NCT03934931) Registered 2nd May 2019 https://clinicaltrials.gov/study/NCT03934931?id=NCT03934931&rank=1Clinical Protocols https://link.springer.com/article/10.1186/s13012-020-01025-8 Funding StatementThis study was supported by a grant from the US National Heart, Lung and Blood Institute: NIH/NHLBI R01HL144406 (AC and DD). The funder had no role in the study design, data collection and analysis in the preparation of the manuscript or decision to publish.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the School of Public Health Research Ethics Committee at the Makerere University College of Health Sciences (Kampala, Uganda), the Uganda National Council for Science and Technology (Kampala, Uganda), and the University of California San Francisco Institutional Review Board (San Francisco, CA, USA).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors with the necessary editing to preserve participant anonymity.